A real-world study of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities
Latest Information Update: 25 Aug 2021
Price :
$35 *
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- 25 Aug 2021 New trial record